Pharmaceutical companies, biotech firms, CROs, and medical device manufacturers in India process the most sensitive personal data category under DPDP — health and clinical data. DPDP Rules 2025 add a new compliance layer with penalties up to ₹250 Cr per incident.
The DPDP Act 2023 applies fully to Indian pharmaceutical companies, biotech firms, contract research organisations (CROs), and medical device manufacturers. Patient health data, clinical trial participant data, adverse event records, and patient support program (PSP) data are all classified as sensitive personal data — attracting the highest DPDP obligations. Companies must obtain explicit, purpose-specific consent for all patient-touching data flows, align pharmacovigilance reporting with the DPDP consent framework, and comply with DPDP Rules 16–17 before transferring clinical trial data to global sponsors. The enforcement deadline is May 13, 2027, and penalties for mishandling patient health data can reach ₹250 crore per incident.
Pharmaceutical companies operate at the intersection of patient data, regulatory mandates, and global data flows. Here's what you're navigating.
Clinical trial participant data — health status, diagnosis, genetic markers, treatment response — is sensitive personal data under DPDP and requires explicit, withdrawable consent. Informed consent collected under ICMR Good Clinical Practice and CDSCO's New Drugs and Clinical Trials Rules (2019) is not automatically DPDP-compliant — companies must layer a separate DPDP consent mechanism. Worse, data routinely shared with global sponsors, CROs, or ethics boards outside India triggers DPDP cross-border transfer rules under Rules 16–17, requiring sponsor-country identification and explicit participant consent covering the overseas transfer.
Adverse drug reaction (ADR) data submitted to WHO's VigiBase and CDSCO's Pharmacovigilance Programme of India (PvPI) contains patient identifiers — age, gender, medical history, concomitant medications. While CDSCO reporting obligations create a legitimate use basis for collecting this data, pharma companies must ensure that PV data processing goes no further than the statutory mandate. Re-use of ADR data for commercial purposes — market research, competitor intelligence, medical representative targeting — requires separate, explicit DPDP consent and cannot be inferred from the PV consent collected at the clinic.
Pharma companies' medical representative (MR) apps and CRM systems collect detailed healthcare professional (HCP) data — NMC registration numbers, prescription frequency by molecule, therapy area preferences, clinic visit records, and personal contact details. This data is personal data under DPDP. Doctors are Data Principals with full DPDP rights, including the right to access the data held about them, correct inaccuracies, and withdraw consent for commercial outreach. Pharma companies need a documented consent framework for HCP engagement — and must stop using doctors' data for any purpose beyond what was consented to at the point of collection.
Disease management programs (DMPs) and patient support programs (PSPs) operated by pharma companies — covering chronic conditions like diabetes, oncology, rare diseases, and respiratory illness — collect the highest-sensitivity data category under DPDP. Diagnosis, medication, adherence patterns, disease progression, and caregiver details are all collected, often digitally via apps or call centres. This data is processed by the pharma company directly (as Data Fiduciary) and shared with third-party program operators, nurses, and diagnostics partners (who become Data Processors). End-to-end DPDP consent, DPA agreements with all processors, and a clear data retention and deletion policy are essential.
Every category below is personal data under the DPDP Act. Health and clinical data categories attract the highest protection obligations as sensitive personal data.
A structured approach built for the complexity of regulated pharmaceutical operations — not a generic data protection checklist.
Document every point at which personal or health data is collected, stored, processed, or shared — across clinical operations, medical affairs, commercial operations (MR apps, CRM), PSPs, and manufacturing. This includes data flows from clinical sites to sponsors, from PSP operators to the pharma company, from MR apps to cloud CRM systems, and from PV teams to CDSCO and WHO. Cross-border flows — to global headquarters, contract research organisations, and regulatory authorities outside India — must be specifically tagged and mapped against DPDP Rules 16–17. Without a complete data map, consent architecture, processor agreements, and rights mechanisms cannot be designed correctly for each data flow.
Design purpose-specific consent mechanisms for every patient-touching program. For clinical trials: layer a DPDP consent addendum onto existing ICMR informed consent documentation — clearly naming the purpose, data categories, retention period, overseas transfer countries, and withdrawal mechanism. For patient support programs: build a multi-purpose consent covering the disease management program, third-party nurse or lab partners, data sharing with the sponsoring pharma company, and any digital health tools. For HCP engagement: implement a consent capture mechanism in MR apps that records what doctors have consented to and enables them to withdraw consent for marketing communications at any time. Consent records must be stored and auditable.
Clinical trial data and PV data routinely cross Indian borders — to global sponsors in the US, EU, or Japan; to CROs; to international ethics committees. DPDP Rules 16–17 govern these transfers. Until India publishes its approved-country whitelist, all cross-border transfers must be based on participant consent that explicitly names the destination country and purpose. Review all existing clinical trial informed consent forms and amend to add DPDP-required cross-border disclosures. Establish Data Processing Agreements (DPAs) with all overseas data processors — global CROs, sponsor companies, lab networks. Implement a cross-border transfer register documenting each transfer's legal basis, destination, and data categories.
Pharmaceutical companies face two critical milestone dates. Clinical trial consent amendments and PSP architecture take time — preparation must begin now.
Fixed-price tools and expert engagements built for India's pharmaceutical sector. Start with a readiness score or go straight to a deep-dive assessment.
Tell us about your organisation and your biggest DPDP concern — clinical trials, PSPs, cross-border transfers, or PV reporting. We'll come prepared with pharma-specific guidance, not generic compliance advice.
Answers to the questions we hear most from pharmaceutical compliance, legal, and medical affairs teams.
One real DPDP development explained in plain English, one practical how-to, one number from our own assessment data. Nothing else — no daily noise, no sales pitch.
No spam. Unsubscribe with one click, anytime.
